The Priority Review

Tag

Chronic Spontaneous Urticaria

1 story

Stories

  1. Clinical trials

    Longbio Pharma registers Phase 3 trial of LP-003 Injection in chronic spontaneous urticaria

    The study plans to enroll 514 participants and plans to start on December 7, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial comparing LP-003 Injection with omalizumab in patients who remain symptomatic despite H1 antihistamine treatment.